课题基金 / 基金详情

Delphinidin: A Novel Agent For Treatment Of Psoriasis

Delphinidin: A Novel Agent For Treatment Of Psoriasis
Delphinidin:一种治疗牛皮癣的新型药物
批准号:
8229942
负责人:
FARRUKH AFAQ
金额:
$18.01万
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-04-01 至 2012-03-31

项目摘要

项目成果

FARRUKH AFAQ的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Psoriasis is characterized by keratinocyte hyperproliferation, loss of granular layer and parakeratotic differentiation. Caspase-14 is a nonapoptotic caspase family member whose expression in the epidermis is confined to the suprabasal layers, and is associated with terminal differentiation. In normal skin, caspase-14 is detected in the cytoplasm and nuclei throughout the suprabasal layers. However, in the parakeratotic regions of psoriatic skin, which are characterized by the lack of nuclear destruction, caspase-14 expression is down-regulated. Strategies to upregulate caspase-14 expression may constitute a novel therapeutic contribution to diseases involving parakeratosis, including psoriasis. Agents that lead to differentiation of epidermal keratinocytes may have therapeutic effects against psoriasis and could also be useful in wound healing and other hyperproliferative skin disorders. Thus, identifying a naturally occurring Complimentary and Alternative Medicine approach with a agent that induces differentiation of epidermal keratinocytes without inducing apoptosis is a highly desirable goal. Delphinidin, a major anthocyanidin in pigmented fruits and vegetables, possesses potent antioxidant activity. Recently, we have shown that topical application of delphinidin inhibited ultraviolet B-mediated formation of DNA damage and TUNEL-positive cells in SKH-1 hairless mouse skin. However, no studies have examined the impact ofdelphinidin treatment on the function of normal human keratinocytes. Our preliminary unpublished studies are noteworthy where we have demonstrated that delphinidin induces procaspase-14 protein and mRNA expression in normal human epidermal keratinocytes. We also found a significant increase in the protein and mRNA expression of involucrin and transglutaminase-1. It is noteworthy that delphinidin under identical treatment conditions did not result in induction of apoptosis. This remarkable distinction forms the basis of this application which is designed to investigate the effect of delphinidin on keratinocyte differentiation both in in vitro human reconstituted skin model system and in preclinical in vivo settings. The central hypothesis to be tested in this application is that "delphinidin will reduce the pathological markers of psoriasiform lesions by inducing the expression of caspase-14, and other markers of early and late differentiation and by suppressing cell proliferation without inducing apoptosis". To test our hypothesis, the following specific aims are proposed: (1) To investigate whether delphinidin treatment increases the distribution and expression level of keratinocyte differentiation markers in in vitro three- dimensional human reconstituted skin as an experimental model system that allow complete epidermal differentiation, and (2) To examine the effect of topical application of delphinidin on pathological markers of psoriasiform lesions under in vivo situation employing flaky skin (fsn/fsn) mice and flaky skin (fsn/fsn) caspase 14-/- mice. Studies will be conducted to determine whether caspase- 14 expression is associated with reduced symptoms of epidermal pathology. PUBLIC HEALTH RELEVANCE: This application intends to define a novel agent delphinidin present in pigmented fruits and vegetables for the treatment of psoriasis and could also be useful in wound healing and other hyperproliferative skin disorders.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Combinatorial Approach for Reducing Invasive Potential of Melanoma Cells
Combinatorial Approach for Reducing Invasive Potential of Melanoma Cells
Delphinidin: A Novel Agent For Treatment Of Psoriasis
Delphinidin: A Novel Agent For Treatment Of Psoriasis
  • 批准号:
    7897113
  • 项目类别:
  • 资助金额:
    $4.26万
  • 财政年份:
    2010
  • 负责人:
    FARRUKH AFAQ
  • 依托单位:
国内基金
海外基金
Novel-miR-1134调控LHCGR的表达介导拟 穴青蟹卵巢发育的机制研究
  • 批准号:
  • 项目类别:
    省市级项目
  • 资助金额:
    10.0万元
  • 批准年份:
    2025
  • 负责人:
    崔文晓
  • 依托单位:
novel-miR75靶向OPR2,CA2和STK基因调控人参真菌胁迫响应的分子机制研究
  • 批准号:
    82304677
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    30.00万元
  • 批准年份:
    2023
  • 负责人:
    边兴博
  • 依托单位:
海南广藿香Novel17-GSO1响应p-HBA调控连作障碍的分子机制
  • 批准号:
    82304658
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    30万元
  • 批准年份:
    2023
  • 负责人:
    刘亚
  • 依托单位:
白术多糖通过novel-mir2双靶向TRADD/MLKL缓解免疫抑制雏鹅的胸腺程序性坏死
  • 批准号:
    32102747
  • 项目类别:
    青年科学基金项目(C类)
  • 资助金额:
    30.0万元
  • 批准年份:
    2021
  • 负责人:
    李婉雁
  • 依托单位: